colorectal%20cancer
COLORECTAL CANCER
Colorectal cancer is a carcinoma arising from the luminal surface of the colon.
It is the 2nd most common cancer in women and third most common cancer in male worldwide. It commonly arises from adenomatous polyps.
It is strongly linked to age with 83% occurring in people ≥60 years old.
Rectal cancer is defined as cancerous lesions located within 12 cm of the anal verge.
Drug Information

Indication: In combination w/ fluoropyrimidine-based chemotherapy for metastatic colon or rectum carcinoma. In combination...

Indication: In combination w/ 5-fluorouracil (5-FU) & folinic acid for advanced colorectal cancer in patients w/o prio...

Indication: Alone or in combination for palliative treatment of malignant tumours, particularly of breast, colon or rectum...

Indication: Advanced colorectal cancer in combination w/ 5-fluorouracil & folinic acid in patients w/o prior chemother...

Indication: Certain megaloblastic anaemia resulting from folic acid deficiency in infant, during pregnancy, in malabsorpti...

Indication: Epidermal growth factor receptor (EGFR) expressing RAS wild-type metastatic colorectal cancer, in combination ...

Indication: In combination w/ docetaxel for locally advanced or metastatic breast cancer after cytotoxic chemotherapy fail...

Indication: In combination w/ 5-fluorouracil (5-FU) & folinic acid (FA) for adjuvant treatment of stage III (Duke's C)...

Indication: Remission of subjective & objective symptoms in head & neck, gastric, colorectal, liver, gallbladder, ...

Indication: Adults w/ wild-type RAS metastatic colorectal cancer (mCRC): 1st-line in combination w/ FOLFOX; 2nd-line in co...

1  /  2
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 02 Jan 2020

Tivozanib as third- or fourth-line therapy improves progression-free survival (PFS) compared with sorafenib in patients with metastatic renal cell carcinoma (mRCC) who have received ≥2 previous systemic treatments, according to results of the phase III, randomized, controlled TIVO-3 trial.